Cookie Settings
We use cookies to provide the best possible website experience for you. This includes cookies that are technically required to ensure a proper functioning of the website, as well as cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for displaying personalized content. You are free to choose the categories you would like to permit. Please note that depending on your settings, the full functionality of the website may no longer be available. Further information can be found in our Privacy Statement and Cookie Statement.
Isolation of cytomegalovirus (CMV)-specific T cells from PBMCs using PE-conjugated CMVpp65/A2 tetramers (courtesy of Prof. Moss, Birmingham, U.K.) and Anti-PE MicroBeads. Cells were positively selected by separation over two MS Columns. |
PBMCs before separation | Enriched CMV-specific T cells |
Anti-PE MicroBeadsFigure 1Isolation of cytomegalovirus (CMV)-specific T cells from PBMCs using PE-conjugated CMVpp65/A2 tetramers (courtesy of Prof. Moss, Birmingham, U.K.) and Anti-PE MicroBeads. Cells were positively selected by separation over two MS Columns. | Anti-PE MicroBeadsFigure 1Isolation of cytomegalovirus (CMV)-specific T cells from PBMCs using PE-conjugated CMVpp65/A2 tetramers (courtesy of Prof. Moss, Birmingham, U.K.) and Anti-PE MicroBeads. Cells were positively selected by separation over two MS Columns. |
Human CLEC9a + cells have been isolated from a debris-rich sample of peripheral blood mononuclear cells (PBMCs) using Anti-CLEC9a-PE, Anti-PE MicroBeads UltraPure, two MS Columns, and a MiniMACS™ Separator. Cells were stained with Anti-CLEC9a-PE (# 130-097-368), CD141 (BDCA-3)-APC (# 130-090-907), and Propidium Iodide Solution (# 130-093-233). Cells were analyzed after gating on viable lymphoid cells. |
Before separation | After separation |
Anti-PE MicroBeadsFigure 2Human CLEC9a + cells have been isolated from a debris-rich sample of peripheral blood mononuclear cells (PBMCs) using Anti-CLEC9a-PE, Anti-PE MicroBeads UltraPure, two MS Columns, and a MiniMACS™ Separator. Cells were stained with Anti-CLEC9a-PE (# 130-097-368), CD141 (BDCA-3)-APC (# 130-090-907), and Propidium Iodide Solution (# 130-093-233). Cells were analyzed after gating on viable lymphoid cells. | Anti-PE MicroBeadsFigure 2Human CLEC9a + cells have been isolated from a debris-rich sample of peripheral blood mononuclear cells (PBMCs) using Anti-CLEC9a-PE, Anti-PE MicroBeads UltraPure, two MS Columns, and a MiniMACS™ Separator. Cells were stained with Anti-CLEC9a-PE (# 130-097-368), CD141 (BDCA-3)-APC (# 130-090-907), and Propidium Iodide Solution (# 130-093-233). Cells were analyzed after gating on viable lymphoid cells. |
We perform both depletion and selection of multiple cell types from cell cultures as well as whole tissues including spleen, lymph nodes, thymus, lung, and bone marrow. Cell samples are then used for RT-qPCR, Flow Cytometric analysis, and re-culturing for functional studies.
Isolation of cytomegalovirus (CMV)-specific T cells from PBMCs using PE-conjugated CMVpp65/A2 tetramers (courtesy of Prof. Moss, Birmingham, U.K.) and Anti-PE MicroBeads. Cells were positively selected by separation over two MS Columns. |
PBMCs before separation | Enriched CMV-specific T cells |
Anti-PE MicroBeadsFigure 1Isolation of cytomegalovirus (CMV)-specific T cells from PBMCs using PE-conjugated CMVpp65/A2 tetramers (courtesy of Prof. Moss, Birmingham, U.K.) and Anti-PE MicroBeads. Cells were positively selected by separation over two MS Columns. | Anti-PE MicroBeadsFigure 1Isolation of cytomegalovirus (CMV)-specific T cells from PBMCs using PE-conjugated CMVpp65/A2 tetramers (courtesy of Prof. Moss, Birmingham, U.K.) and Anti-PE MicroBeads. Cells were positively selected by separation over two MS Columns. |
Human CLEC9a + cells have been isolated from a debris-rich sample of peripheral blood mononuclear cells (PBMCs) using Anti-CLEC9a-PE, Anti-PE MicroBeads UltraPure, two MS Columns, and a MiniMACS™ Separator. Cells were stained with Anti-CLEC9a-PE (# 130-097-368), CD141 (BDCA-3)-APC (# 130-090-907), and Propidium Iodide Solution (# 130-093-233). Cells were analyzed after gating on viable lymphoid cells. |
Before separation | After separation |
Anti-PE MicroBeadsFigure 2Human CLEC9a + cells have been isolated from a debris-rich sample of peripheral blood mononuclear cells (PBMCs) using Anti-CLEC9a-PE, Anti-PE MicroBeads UltraPure, two MS Columns, and a MiniMACS™ Separator. Cells were stained with Anti-CLEC9a-PE (# 130-097-368), CD141 (BDCA-3)-APC (# 130-090-907), and Propidium Iodide Solution (# 130-093-233). Cells were analyzed after gating on viable lymphoid cells. | Anti-PE MicroBeadsFigure 2Human CLEC9a + cells have been isolated from a debris-rich sample of peripheral blood mononuclear cells (PBMCs) using Anti-CLEC9a-PE, Anti-PE MicroBeads UltraPure, two MS Columns, and a MiniMACS™ Separator. Cells were stained with Anti-CLEC9a-PE (# 130-097-368), CD141 (BDCA-3)-APC (# 130-090-907), and Propidium Iodide Solution (# 130-093-233). Cells were analyzed after gating on viable lymphoid cells. |
We perform both depletion and selection of multiple cell types from cell cultures as well as whole tissues including spleen, lymph nodes, thymus, lung, and bone marrow. Cell samples are then used for RT-qPCR, Flow Cytometric analysis, and re-culturing for functional studies.
Seems like you are coming from USA!
Do you want to visit our website in your country?
Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.